Stock Taper
SCREENER COMPARE ANY 2 STOCKS
SPRO
SPERO THERAPEUTICS, INC.
NASDAQ
$1.20
▼ DOWN 0.83% (-0.01)

KEY STATISTICS

Market Cap$69.48 M
52w High$3.08
52w Low$1.08
Dividend Yield0.52%
FrequencyQuarterly
P/E5.00
Volume306.16K
Shares Out.57.90M

COMPANY

LEADERSHIP

Esther Rajavelu
CHIEF EXECUTIVE
Esther Rajavelu

COMPENSATION 2026

Salary$244,153
Stock Awards$603,380
Incentive Plan Pay$307,912
All Other Comp.$416,919
Total$2,025,178

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 2, 2017
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
25

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.—
NOV
12
THU

PRICE

$1.20 ▼ DOWN 0.83% (−$0.01)
$1.19$1.20$1.219:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM1.20

About Spero Therapeutics, Inc.

https://sperotherapeutics.com ↗

Spero Therapeutics is a clinical-stage biopharma focused on developing treatments for MDR bacterial infections and rare diseases, with key candidates like tebipenem HBr, SPR206, and SPR720.

INDUSTRY

Biotechnology

A PRODUCT SPERO THERAPEUTICS, INC. IS KNOWN FOR

Tebipenem HBr (tebipenem pivoxil hydrobromide)
Tebipenem HBr (tebipenem pivoxil hydrobromide)

Tebipenem HBr is an investigational oral carbapenem antibiotic for cUTI, potentially the first approved oral carbapenem in the U.S., with GSK resubmitting an NDA expected decision in late 2026.

COMPETITORS

COMPETITOR
ACXP COMPARE
GSK COMPARE
INVA COMPARE

Revenue by Products

IconPRODUCTQ2-2025Q3-2025Q4-2025Q1-2026
Collaboration Revenue— — $12.57M —
Grant Revenue$2.39M $2.39M ▲$1.64M ▼—
Collaboration Revenue Related Party$11.8M $3.05M ▼$27.08M ▲$258K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
16
LISTED HERE
4
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.4M
IWC
0.01% · 153.2K
QQQS
0.21% · 39.5K
DFAT
0.00% · 16.1K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
39.18%
HOLDERS
79
TOP 12 OF 79 · RANKED BY POSITION SIZE
GP
Gsk Plc
9.2M sh · $21.41M
Pfizer Inc
2.4M sh · $5.5M
Vanguard Group Inc
2.1M sh · $4.85M
Anson Funds Management LP
1.6M sh · $3.01M
Renaissance Technologies LLC
1.5M sh · $2.73M
Atlas Venture Associates Xi, LLC
1.4M sh · $26.7M
Atlas Venture Associates Ix, LLC
1.4M sh · $1.64M
Alphabet Inc.
890.0K sh · $2.08M
Two Sigma Investments, LP
885.6K sh · $2.07M
Geode Capital Management, LLC
529.2K sh · $1.23M
Blackrock Inc.
483.4K sh · $628.42K
Vhcp Management Ii, LLC
474.0K sh · $4.56M

RATINGS SNAPSHOT

Overall rating: B+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity4
Return On Assets5
Debt To Equity4
Price To Earnings2
Price To Book2
Overall Score3

INSIDER TRADES

★
OFFICER: CHIEF MEDICAL OFFICER
Zack Debra
Purchase · 324.7K shares
2026-08-03
★
OFFICER: CHIEF MEDICAL OFFICER
Zack Debra
Purchase · 162.3K shares
2026-08-03
★
Zack Debra
— · —
2026-08-03
★
DIRECTOR
Smith Cynthia
Purchase · 10.0K shares
2026-06-23

SECTORS PEERS

PEERPRICE
IRD$3.69COMPARE
ABOS$2.92COMPARE
CRBP$10.91COMPARE
HURA$2.11COMPARE
SEER$1.98COMPARE
CGTX$1.02COMPARE
INO$1.29COMPARE
MCRB$5.11COMPARE